Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
ViaCyte

ViaCyte

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.

Timeline

June 19, 2021
ViaCyte raises $45M in Series D funding.

The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.

June 18, 2021
ViaCyte raises a $45,000,000 series D round.
May 26, 2020
ViaCyte raises a $27,000,000 series D round.
March 2020
ViaCyte raises a $32,600,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and TPG Capital Asia.
September 2018
ViaCyte raises a $10,000,000 convertible note from W. L. Gore and Associates.
December 2017
ViaCyte raises a $1,400,000 grant from California Institute for Regenerative Medicine.
July 2016
ViaCyte raises a $3,900,000 grant.
September 2014
ViaCyte raises a $16,600,000 grant from California Institute for Regenerative Medicine.
August 2014
ViaCyte raises a $5,400,000 series C round.
August 2014
ViaCyte raises a $20,000,000 venture round from Johnson & Johnson Innovation.

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes

Beyondtype1

Web

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

ViaCyte, Inc.

Web

ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial

Benedict Jephcote

Web

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

ViaCyte, Inc.

Web

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 13, 2021
FierceBiotech
Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia. Timothy Kieffer will join the clinical-stage regenerative medicine biotech as CSO.
ViaCyte, Inc.
June 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients...
FinSMEs
June 19, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Kyle LaHucik
June 9, 2021
FierceBiotech
ViaCyte snagged $45 million in a new tranche of financing to expand on a 2018 series D worth $80 million. The money will fund the biotech's work on two midstage candidates for type 1 diabetes, and it comes just a day after the biotech said its chief scientific officer is leaving.
BioSpace
June 8, 2021
BioSpace
ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.